Jazz Pharmaceuticals and BeOne Medicines side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Jazz Pharmaceuticals | BeOne Medicines |
|---|---|---|
| Phase 1 | 38% | BeOne Medicines: 16 of its 24 programs at phase 1
and 11 more — sign in to see them all |
| Phase 2 | Jazz Pharmaceuticals: 2 of its 8 programs at phase 2
| BeOne Medicines: 1 of its 24 programs at phase 2
|
| Phase 3 | Jazz Pharmaceuticals: 1 of its 8 programs at phase 3
| BeOne Medicines: 6 of its 24 programs at phase 3
and 1 more — sign in to see them all |
| Approved, new studies | Jazz Pharmaceuticals: 2 of its 8 programs at approved, new studies
| BeOne Medicines: 1 of its 24 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharmaceuticals5 readouts · 1 phase 3 | Jazz Pharmaceuticals, Nov ’26: 1 program whose next study reaches primary completion
| Jazz Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion
| · | Jazz Pharmaceuticals, Feb ’27: 1 program whose next study reaches primary completion
| Jazz Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion
| · | · | · | · | Jazz Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · |
| BeOne Medicines10 readouts · 1 phase 3 | BeOne Medicines, Nov ’26: 4 programs whose next study reaches primary completion
| BeOne Medicines, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| · | · | BeOne Medicines, Mar ’27: 1 program whose next study reaches primary completion
| · | · | · | BeOne Medicines, Jul ’27: 2 programs whose next study reaches primary completion
| · | BeOne Medicines, Sep ’27: 1 program whose next study reaches primary completion
| BeOne Medicines, Oct ’27: 1 program whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Jazz Pharmaceuticals
New programs 1
- JZP269phase 1 · first study · Sep 4
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 3
- lurbinectedinphase 2 · Jan 2028 → Aug 2029 (+18 mo) · moved Nov 6 · NCT07459634
- JZP047phase 1 · Jul 2026 → Nov 2026 (+5 mo) · moved Oct 23 · NCT07377539
- zeltipronephase 1 · Jul 2026 → Mar 2027 (+9 mo) · moved Oct 23 · NCT04541082
BeOne Medicines
New programs 6
- BON-C1393phase 1 · first study · Oct 23
- BON-107phase 1 · first study · Oct 22
- BG-92505phase 1 · first study · Oct 21
- BON-106phase 1 · first study · Oct 19 · Neoplasm Metastasis
- BG-T0920phase 1 · first study · Oct 15 · Lymphoma, Large B-Cell, Diffuse
- BG-T0050phase 1 · first study · Oct 12 · Lymphoma, Large B-Cell, Diffuse
Reached a new phase 2
- Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033phase 3 · Sep 17 · Carcinoma, Hepatocellular
- Anti-B7-H4 Antibody Drug Conjugate BG-C9074phase 3 · Sep 3 · Carcinoma, Ovarian Epithelial
Study stopped 0
None
Primary completion later 2
- PRMT5 Inhibitor BGB-58067phase 1 · Sep 2027 → Aug 2028 (+11 mo) · moved Oct 20 · NCT06589596
- tacabrutidegphase 2 · Nov 2026 → Mar 2027 (+4 mo) · moved Oct 5 · NCT05006716
Where they overlap
Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.
| Condition | Jazz Pharmaceuticals | BeOne Medicines |
|---|---|---|
| Breast Neoplasmsboth · compare here | Jazz Pharmaceuticals in Breast Neoplasms: 2 programs
Their studies: Jazz Pharmaceuticals’ studies of Breast Neoplasms in search | BeOne Medicines in Breast Neoplasms: 3 programs
Their studies: BeOne Medicines’ studies of Breast Neoplasms in search |
| Stomach Neoplasmsboth · compare here | Jazz Pharmaceuticals in Stomach Neoplasms: 1 program
Their studies: Jazz Pharmaceuticals’ studies of Stomach Neoplasms in search | BeOne Medicines in Stomach Neoplasms: 1 program
Their studies: BeOne Medicines’ studies of Stomach Neoplasms in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.